Evaluation of Neutrophil Activation Biomarkers in Response to Programmed Cell Death Protein-1 (PD-1) and Toll-like Receptor 9 (TLR-9) Inhibition in Triple Negative Breast Cancer.

IF 2.9 3区医学 Q2 ONCOLOGY

Clinical breast cancer Pub Date : 2025-01-31 DOI:10.1016/j.clbc.2025.01.013

Sara Youssry, Amina Hussein, Nadia Abd El Moneim, Alaa Samy, Asmaa Mostafa, Mohamed H Sultan

{"title":"Evaluation of Neutrophil Activation Biomarkers in Response to Programmed Cell Death Protein-1 (PD-1) and Toll-like Receptor 9 (TLR-9) Inhibition in Triple Negative Breast Cancer.","authors":"Sara Youssry, Amina Hussein, Nadia Abd El Moneim, Alaa Samy, Asmaa Mostafa, Mohamed H Sultan","doi":"10.1016/j.clbc.2025.01.013","DOIUrl":null,"url":null,"abstract":"Background and objective: Activation of neutrophils has proven to be useful in different models of cancer therapy. However, more comprehensive studies are required to further characterize these potential targets. Thus, we aimed to evaluate the effects of programmed cell death protein-1 (PD-1) and toll-like receptor 9 (TLR-9) inhibition on markers of neutrophil activation in different breast cancer subtypes.Methods: Neutrophils were cultured and treated with PD-1 and TLR-9 inhibitors after being isolated from 43 triple negative breast cancer (TNBC), 31 non-TNBC patients and 30 healthy females. Enzyme linked immunosorbent assay (ELISA) was then used to detect neutrophil elastase (NE) and myeloperoxidase (MPO) in culture supernatants.Results: The results revealed that increased NE and MPO were significantly associated with advanced clinical stage and vascular invasion, respectively. In addition, treatment with either anti-PD-1 or anti-TLR-9 was associated with a significant decrease in NE and MPO levels of both TNBC and non-TNBC samples compared to untreated samples. Moreover, the ameliorative effect of both treatments was observed to be more obvious on MPO levels compared to NE levels in breast cancer subtypes.Conclusion: These results may highlight the possible therapeutic role of PD-1 and TLR-9 inhibitors in modulating neutrophil activation markers (NE and MPO) in breast cancer subtypes.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2025.01.013","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: Activation of neutrophils has proven to be useful in different models of cancer therapy. However, more comprehensive studies are required to further characterize these potential targets. Thus, we aimed to evaluate the effects of programmed cell death protein-1 (PD-1) and toll-like receptor 9 (TLR-9) inhibition on markers of neutrophil activation in different breast cancer subtypes.

Methods: Neutrophils were cultured and treated with PD-1 and TLR-9 inhibitors after being isolated from 43 triple negative breast cancer (TNBC), 31 non-TNBC patients and 30 healthy females. Enzyme linked immunosorbent assay (ELISA) was then used to detect neutrophil elastase (NE) and myeloperoxidase (MPO) in culture supernatants.

Results: The results revealed that increased NE and MPO were significantly associated with advanced clinical stage and vascular invasion, respectively. In addition, treatment with either anti-PD-1 or anti-TLR-9 was associated with a significant decrease in NE and MPO levels of both TNBC and non-TNBC samples compared to untreated samples. Moreover, the ameliorative effect of both treatments was observed to be more obvious on MPO levels compared to NE levels in breast cancer subtypes.

Conclusion: These results may highlight the possible therapeutic role of PD-1 and TLR-9 inhibitors in modulating neutrophil activation markers (NE and MPO) in breast cancer subtypes.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical breast cancer 医学-肿瘤学

CiteScore

5.40

自引率

3.20%

发文量

174

审稿时长

48 days

期刊介绍： Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.